Article
Oncology
Yangyang Zhang, Lingxiu Zeng, Meng Wang, Zhenwei Yang, Hailin Zhang, Liping Gao, Ranran Zhang, Jialong Liu, Wenqing Shan, Ying Chang, Lan Liu, Qiu Zhao, Yong Li, Jing Liu
Summary: The study found that RIG-I plays an important role in the immunotherapy of colon cancer by maintaining the stability of PD-L1 to promote immune evasion. Silencing RIG-I increases the sensitivity of tumor cells to T cell killing and slows down the growth of colon tumors. High expression of RIG-I promotes tumor progression and enhances the sensitivity to PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Shih-Hsun Chen, Pawel K. Dominik, Jessica Stanfield, Sheng Ding, Wenjing Yang, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C. Lindquist, Javier Chaparro-Riggers, Shahram Salek-Ardakani
Summary: The study developed a novel affinity-tuned bispecific antibody targeting CD47 and PD-L1 to antagonize innate and adaptive immune checkpoint pathways. This antibody showed enhanced selectivity in the tumor microenvironment and improved therapeutic window compared to monotherapies or combination therapies with alpha CD47 and alpha PD-L1. The bispecific treatment uniquely modulated myeloid and T cells, providing potential for clinical development to improve patient outcomes over current PD-(L)1 and CD47-targeted therapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Zhang-Wei Hu, Wei Sun, Yi-Hui Wen, Ren-Qiang Ma, Lin Chen, Wen-Qing Chen, Wen-Bin Lei, Wei-Ping Wen
Summary: CD69 and SBK1 are potential biomarkers to predict response to cancer immunotherapy, guiding treatment decisions for precision therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Libin Zhang, Yanhui Chen, Han Wang, Zheyuan Xu, Yang Wang, Sixing Li, Jun Liu, Yun Chen, Hongli Luo, Lijia Wu, Ying Yang, Henghui Zhang, Hao Peng
Summary: CD8+PD-L1+ tumor-infiltrating lymphocytes in the tumor microenvironment of non-small cell lung cancer can serve as an indicator of a hot but immunosuppressive environment related to high tumor mutation burden. In immunotherapy, blocking the PD-1 pathway can help alleviate immunosuppression and lead to better treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu
Summary: The expression of NKG2A and PD-L1 together can be used as a combinatorial biomarker to predict the therapeutic response to immune checkpoint blockade in patients with muscle-invasive bladder cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Sheng-ming Xu, Chao-ji Shi, Rong-hui Xia, Li-zhen Wang, Zhen Tian, Wei-min Ye, Liu Liu, Shu-li Liu, Chun-ye Zhang, Yu-hua Hu, Rong Zhou, Yong Han, Yu Wang, Zhi-yuan Zhang, Jiang Li
Summary: This study aimed to investigate the clinicopathological, tumor immune microenvironmental, and molecular features of HPV(+)OPSCC based on PD-L1 expression. The results showed that high PD-L1 expression was associated with higher tumor mutation burden, CD8(+) T cell infiltration, and immune-related genomic alterations. This study provides valuable insights into the immune features of HPV(+)OPSCC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Suyeon Kim, Roun Heo, Seok Ho Song, Kwon-Ho Song, Jung Min Shin, Se Jin Oh, Hyo-Jung Lee, Jo Eun Chung, Jae Hyung Park, Tae Woo Kim
Summary: Foreignization of tumor cells by delivering a non-self foreign antigen into tumors is an effective strategy for tumor rejection. However, immune-suppressive factors in the tumor microenvironment limit the immune response against tumor antigens. Blocking PD-L1 on both tumor cells and dendritic cells can enhance the induction of tumor-reactive T cells and strengthen the anti-tumor immunity initiated by tumor-foreignization.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Oncology
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng
Summary: Our study reveals that eEF2K is correlated with therapeutic response and prognosis in melanoma patients treated with anti-PD-1 therapy. We also show that eEF2K plays a vital role in regulating the tumor immune microenvironment by controlling PD-L1 expression. In addition, combining eEF2K inhibition with ICB therapy may provide a potential combination therapeutic strategy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Qi Zhang, Jing Pan, Donghai Xiong, Junjun Zheng, Kristi N. McPherson, Sangbeom Lee, Mofei Huang, Yitian Xu, Shu-hsia Chen, Yian Wang, Lea Hildebrandt Ruiz, Ming You
Summary: Delivery of aerosolized microRNAs targeting PD-L1 can effectively prevent the development and progression of lung cancer. In this study, aerosolized miR-138-5p and miR-200c miRNA mimics were found to inhibit B(a)P-induced lung adenomas and NTCU-induced lung squamous cell carcinomas with no detectable side effects. These miRNAs were also shown to inhibit PD-L1 expression and promote the immune response against cancer cells by increasing CD4+ and CD8+ T cells while reducing PD-1 expression and T-regulatory cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Laure Chardin, Alexandra Leary
Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a high recurrence rate, despite many patients responding effectively to current treatments. In order to improve outcomes, further research into the immune microenvironment and the development of effective therapies are urgently needed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Stella A. Martomo, Jeegar Patel
Summary: KD033 is an immunocytokine composed of an anti-human-PD-L1 antibody and IL-15/IL-15 receptor sushi-domain complex. It has shown efficacy in tumor models resistant to anti-PD-1/PD-L1 checkpoint blockers. KD033 was effective in both low and high PD-L1-expressing tumors. It reproduced the anti-tumor efficacy in syngeneic models and induced changes in transcriptomic profiles and immune-related genes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Immunology
Tiantian Wu, Caijin Tang, Renchuan Tao, Xiangzhi Yong, Qiaozhi Jiang, Cong Feng
Summary: The research found that PD-L1 is highly expressed in oral squamous cell carcinoma (OSCC), correlated with worse survival, and related to macrophage infiltration and EMT process. Patients with high PD-L1 expression may benefit from ICI treatment and show higher sensitivity to certain chemical drugs.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Chunhong Hu, Lishu Zhao, Wenliang Liu, Songqing Fan, Junqi Liu, Yuxuan Liu, Xiaohan Liu, Long Shu, Xianling Liu, Ping Liu, Chao Deng, Zhenhua Qiu, Chen Chen, Yi Jiang, Qingchun Liang, Lingling Yang, Yang Shao, Qiongzhi He, Danlei Yu, Yue Zeng, Yizheng Li, Yue Pan, Sujuan Zhang, Shenghao Shi, Yurong Peng, Fang Wu
Summary: Patients with MPLCs often present in non-smoking women younger than 60 years, with EGFR being the most frequently mutated gene. Shared putative driver genes between tumors indicate more aggressive tumors. MPLCs exhibit low TMB, low PD-L1 positivity, and a heterogeneous immune infiltration landscape.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Mao Lin, Zongyao Huang, Yingfu Chen, Hongtao Xiao, Ting Wang
Summary: This review systematically summarizes the outcomes of lung cancer patients with chronic obstructive pulmonary disease (COPD) after anti-PD-1/PD-L1 treatment and discusses the role of COPD in regulating the tumor immune microenvironment (TIME) in lung cancer immunotherapy, providing novel insights for the clinical treatment of lung cancer patients with COPD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Shinya Neri, Hiroko Hashimoto, Hiroaki Kii, Hirotada Watanabe, Kenkichi Masutomi, Takeshi Kuwata, Hiroshi Date, Masahiro Tsuboi, Koichi Goto, Atsushi Ochiai, Genichiro Ishii
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2016)
Review
Pharmacology & Pharmacy
Genichiro Ishii, Atsushi Ochiai, Shinya Neri
ADVANCED DRUG DELIVERY REVIEWS
(2016)
Review
Pharmacology & Pharmacy
Yifan Wang, Weiye Deng, Nan Li, Shinya Neri, Amrish Sharma, Wen Jiang, Steven H. Lin
FRONTIERS IN PHARMACOLOGY
(2018)
Article
Multidisciplinary Sciences
Masayuki Ishibashi, Shinya Neri, Hiroko Hashimoto, Tomoyuki Miyashita, Tatsuya Yoshida, Yuka Nakamura, Hibiki Udagawa, Keisuke Kirita, Shingo Matsumoto, Shigeki Umemura, Kiyotaka Yoh, Seiji Niho, Masahiro Tsuboi, Kenkichi Masutomi, Koichi Goto, Atsushi Ochiai, Genichiro Ishii
SCIENTIFIC REPORTS
(2017)
Article
Oncology
Tomoyuki Miyashita, Tomokazu Omori, Hiroshi Nakamura, Masato Sugano, Shinya Neri, Satoshi Fujii, Hiroko Hashimoto, Masahiro Tsuboi, Atsushi Ochiai, Genichiro Ishii
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2019)
Article
Oncology
Takashi Sakai, Keiju Aokage, Shinya Neri, Hiroshi Nakamura, Shogo Nomura, Kenta Tane, Tomohiro Miyoshi, Masato Sugano, Motohiro Kojima, Satoshi Fujii, Takeshi Kuwata, Atsushi Ochiai, Akira Iyoda, Masahiro Tsuboi, Genichiro Ishii
Article
Oncology
Shinya Neri, Toshi Menju, Terumasa Sowa, Yojiro Yutaka, Daisuke Nakajima, Masatsugu Hamaji, Akihiro Ohsumi, Toyofumi F. Chen-Yoshikawa, Toshihiko Sato, Makoto Sonobe, Akihiko Yoshizawa, Hironori Haga, Hiroshi Date
Article
Oncology
Ismail M. Meraz, Mourad Majidi, Feng Meng, RuPing Shao, Min Jin Ha, Shinya Neri, Bingliang Fang, Steven H. Lin, Peggy T. Tinkey, Elizabeth J. Shpall, Jeffrey Morris, Jack A. Roth
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Cell Biology
Shoshi Hisamitsu, Tomoyuki Miyashita, Hiroko Hashimoto, Shinya Neri, Masato Sugano, Hiroshi Nakamura, Shota Yamazaki, Atsushi Ochiai, Koichi Goto, Masahiro Tsuboi, Genichiro Ishii
Article
Multidisciplinary Sciences
Nan Li, Yifan Wang, Shinya Neri, Yuanli Zhen, Lon Wolf R. Fong, Yawei Qiao, Xu Li, Zhen Chen, Clifford Stephan, Weiye Deng, Rui Ye, Wen Jiang, Shuxing Zhang, Yonghao Yu, Mien-Chie Hung, Junjie Chen, Steven H. Lin
NATURE COMMUNICATIONS
(2019)
Article
Multidisciplinary Sciences
Bhanu Prasad Venkatesulu, Amrish Sharma, Julianne M. Pollard-Larkin, Ramaswamy Sadagopan, Jessica Symons, Shinya Neri, Pankaj K. Singh, Ramesh Tailor, Steven H. Lin, Sunil Krishnan
SCIENTIFIC REPORTS
(2019)
Article
Cell Biology
Tomoyuki Miyashita, Shinya Neri, Hiroko Hashimoto, Asami Akutsu, Masato Sugano, Satoshi Fujii, Atsushi Ochiai, Genichiro Ishii
JOURNAL OF CELLULAR PHYSIOLOGY
(2020)
Article
Oncology
Jun Suzuki, Keiju Aokage, Shinya Neri, Takashi Sakai, Hiroko Hashimoto, Yinghan Su, Shota Yamazaki, Hiroshi Nakamura, Kenta Tane, Tomohiro Miyoshi, Masato Sugano, Motohiro Kojima, Satoshi Fujii, Takeshi Kuwata, Atsushi Ochiai, Masahiro Tsuboi, Genichiro Ishii
Summary: PDPN+ CAFs in lung squamous cell carcinoma showed higher TGFB1 expression and were associated with infiltration of CD204(+) TAMs, indicating that PDPN+ CAFs were related to the immunosuppressive tumor microenvironment.
Article
Oncology
Shinya Neri, Tomoyuki Miyashita, Hiroko Hashimoto, Yoshitaka Suda, Masayuki Ishibashi, Hiroaki Kii, Hirotada Watanabe, Takeshi Kuwata, Masahiro Tsuboi, Koichi Goto, Toshi Menju, Makoto Sonobe, Hiroshi Date, Atsushi Ochiai, Genichiro Ishii